To evaluate the long-term efficacy of LY2127399 as assessed by the individual components of the ACR Core set, as well as ACR20, ACR50, ACR70, and ACR-N [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

To evaluate the impact of long term administration of LY2127399 on patient-reported outcomes as measured by the Functional Assessment of Chronic Illness Therapy(FACIT) [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

To evaluate the long-term efficacy of LY2127399 as assessed by the DAS28 [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

To evaluate the long-term efficacy of LY2127399 as assessed by the EULAR28 [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

To evaluate the impact of long term administration of LY2127399 on patient reported outcomes as measured by the Medical Outcomes Study 36-item Short Form Health Survey (SF-36) [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation

Have participated in either Study BCDG or Study BCDH

Exclusion Criteria:

Have had, during Study BCDG or Study BCDH, any safety event,(including having a recent, ongoing, or serious infection, a serious drug reaction, or any AE that caused discontinuation from treatment) that in the opinion of the investigator poses an unacceptable risk to participation in the study.

Have received, during Study BCDG or Study BCDH, any drug not allowed by the study protocol including unapproved drugs, biologic DMARDs, or live vaccines.

Enrollment in any other clinical trial involving off-label use of an investigational drug or device, or enrollment in any other type of medical research.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00837811